» Articles » PMID: 37409096

DNA Methylation Biomarkers Distinguishing Early-stage Prostate Cancer from Benign Prostatic Hyperplasia

Abstract

Background: DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen.

Methods: A total of 42 PCa patients and 11 BPH patients were recruited. Genomic DNA was purified from tissues and used for the library preparation of the target-enriched methylome with enzymatic conversion and a Twist 85 Mbp EM-seq panel. Paired-end sequencing (150 bp) was performed using NovaSeq 6000 or NextSeq 550. After quality control, including adapter trimming and de-duplication of raw sequencing data, differential methylation patterns were analyzed between the BPH and PCa groups.

Results: We report DNA methylation patterns existing between BPH and PCa. The major finding is that broad hypermethylation occurred at genic loci in PCa tissues as compared to the BPH. Gene ontology analysis suggested that hypermethylation of genic loci involved in chromatin and transcriptional regulation is involved in cancer progression. We also compared PCa tissues with high Gleason scores to tissues with low Gleason scores. The high-Gleason PCa tissues showed hundreds of focal differentially methylated CpG sites corresponding to genes functioning in cancer cell proliferation or metastasis. This suggests that dissecting early-to-advanced-grade cancer stages requires an in-depth analysis of differential methylation at the single CpG site level.

Conclusions: Our study reports that enzymatic methylome sequencing data can be used to distinguish PCa from BPH and advanced PCa from early-stage PCa. The stage-specific methylation patterns in this study will be valuable resources for diagnostic purposes as well as further development of liquid biopsy approaches for the early detection of PCa.

Citing Articles

From microscopes to molecules: The evolution of prostate cancer diagnostics.

Tao J, Bian X, Zhou J, Zhang M Cytojournal. 2024; 21:29.

PMID: 39391208 PMC: 11464998. DOI: 10.25259/Cytojournal_36_2024.


A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study.

Liu B, Wang X, Yang Z, Yin Z, Tang C, He Y Sci Rep. 2024; 14(1):23120.

PMID: 39367121 PMC: 11452698. DOI: 10.1038/s41598-024-73466-w.


PDIA2 is associated with the prognosis of prostate cancer, and downregulation of PDIA2 delays the progression of prostate cancer cells.

Zhou Q, Ge Y, Ma S, Xiong Z, Wang Y, Li L Sci Rep. 2024; 14(1):22064.

PMID: 39333312 PMC: 11436862. DOI: 10.1038/s41598-024-73361-4.


Exploring the potential of 7-T magnetic resonance imaging on patients with clinically significant prostate cancer: visibility and size perspective.

Ahn H, Kim J, Hwang S, Hong S, Byun S, Song S Prostate Int. 2024; 12(2):79-85.

PMID: 39036759 PMC: 11255944. DOI: 10.1016/j.prnil.2024.02.001.


A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).

Sepe P, Procopio G, Pircher C, Basso U, Caffo O, Cappelletti V Ther Adv Med Oncol. 2024; 16:17588359231217958.

PMID: 38264520 PMC: 10804904. DOI: 10.1177/17588359231217958.


References
1.
Vaisvila R, Ponnaluri V, Sun Z, Langhorst B, Saleh L, Guan S . Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. Genome Res. 2021; 31(7):1280-1289. PMC: 8256858. DOI: 10.1101/gr.266551.120. View

2.
Park Y, Wu H . Differential methylation analysis for BS-seq data under general experimental design. Bioinformatics. 2016; 32(10):1446-53. DOI: 10.1093/bioinformatics/btw026. View

3.
Guerra-Calderas L, Gonzalez-Barrios R, Herrera L, Cantu de Leon D, Soto-Reyes E . The role of the histone demethylase KDM4A in cancer. Cancer Genet. 2015; 208(5):215-24. DOI: 10.1016/j.cancergen.2014.11.001. View

4.
Bai Y, Yang C, Wu R, Huang L, Song S, Li W . YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma. Front Oncol. 2019; 9:332. PMC: 6509179. DOI: 10.3389/fonc.2019.00332. View

5.
Kim J, Dhanasekaran S, Prensner J, Cao X, Robinson D, Kalyana-Sundaram S . Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011; 21(7):1028-41. PMC: 3129246. DOI: 10.1101/gr.119347.110. View